Tag - Chardan


Chardan starts DURECT at buy; PT $7

200 Chardan Capital Markets launched coverage of DURECT (NASDAQ:DRRX) with a “buy” rating and price target of $7. The stock closed at $1.76 on Oct. 29. “We expect that DURECT’s lead pipeline asset, DUR-928, will...

Axcella Logo

Chardan starts Axcella Health at buy; PT $16

Chardan Capital Markets initiated coverage of Axcella Health (NASDAQ:AXLA) with a “buy” rating and $16 price target. The stock closed at $4.45 on Oct. 26 “We expect that Axcella’s pipeline of endogenous metabolic...

Chardan president, Jonas Grossman, talks SPACs

Jonas Grossman As president of Chardan, an independent, global investment bank specializing in healthcare, disruptive technologies, and special purpose acquisition companies (SPACs), Jonas Grossman takes a worldwide...